Maria A. Pabón, MD

APOs and cardiometabolic risk are tightly linked. In our new HCHS/SOL analysis published in @AJPCardio, preconception cardiometabolic abnormalities were associated with higher odds of APOs, with a clear dose response by metabolic syndrome burden. @OdaymeMD sciencedirect.com/science/articl…

Our analysis of aldosterone parameters and CVD outcomes in ARIC is now online 👇

🫶

What an incredible day at the MGB SCAD symposium this past October 🎉 Co-hosted by the MGB Women's Heart Health Program and the SCAD Alliance, we brought together 220+ participants from 10 states and 6 countries for a SCAD patient-centered symposium.💙🌎

Thrilled to welcome our new incoming Cardiology Fellows! 🎓❤️ Can’t wait to see the talent, curiosity, and compassion you’ll bring to the program. Here’s to years of learning, teamwork, and advancing heart care together. #CardioTwitter #MedTwitter

Lots of confusion about menopausal hormone therapy right now —who should get it, when to start, and what is the🫀 risk? Our new review led by @BrighamMedRes Ruby Guo covers timing, route, and CV risk stratification for midlife women. 🔗: rdcu.be/eSUqJ

Profesor Luis Enrique Caro Henao. El Maestro. Su última lección. 3 de diciembre de 2025 Facultad de Medicina Universidad Nacional de Colombia

🫀 Does sex matter in response to aficamten? In SEQUOIA-HCM, women with obstructive #HCM were older & had worse baseline status (↑NT-proBNP, ↑LVOT gradients, ↓pVO₂) — yet showed similar improvements in pVO₂, LVOT gradient, and KCCQ as men. #AHA25 @SheilaHegde @wendywangmd

Someone needs to listen to this voice of reason @hmkyale @JACCJournals because we are the only country that makes practicing as a cardiologist so onerous, expensive, & irrelevant. I do MOC every 3 months & the questions are not helpful to my practice. I leave it to last minute because of lack of time in this thing called life. I hate it, & I hate the exam. Let us do the ACC course every 5 years. Let us gather educational credits anytime. Something other than what we have. Don't make us pay. We pay for enough things. Let ACC run it. It is our cardiology home not the ABIM. jacc.org/doi/10.1016/j.…

Application deadline for new @ACCinTouch #ACCEarlyCareer initiative, Using Her Voice Scholars Program led by 💫@emilyswlau & @marysia_tweet, extended to 11/7 Learn more and apply! acc.org/Membership/Joi… @nbwiggins @adityadoc1 @BrentonBauerMD

Thrilled to share our paper in @JACCJournals @ankeetbhatt @mvaduganathan @hfcollaboratory 🫀This work proposes a standardized Cardiovascular-Kidney-Metabolic Medical Therapy Optimization Score to enhance the capture of background data collection across CKM in trials

@Deoliveiragdc @mvaduganathan @JACCJournals @ankeetbhatt @hfcollaboratory 👏👏👏

Sleep Apnea and Cardiac Structure and Function in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PARAGON-HF Trial Patients with HFpEF and sleep apnea exhibited evidence of LV remodeling, subclinical biventricular myocardial dysfunction, and an increased risk of adverse CV events compared to those without sleep apnea, regardless of LVEF. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @JavedButler1 @mvaduganathan @AndrewJSauer @ankeetbhatt @DrMarthaGulati @BiykemB @hfcollaboratory @SJGreene_md @gcfmd @dranulala @GMCRosano @Hragy @AnastasiaSMihai onlinejcf.com/article/S1071-…

Now in @JACCJournals led by #HFC members @mvaduganathan, @akshaydesaimd @scottdsolomon @orlyvardeny et al. This study from the DELIVER trial, examines whether the degree of LVEF improvement influences in the therapeutic effects of Dapagliflozin in HFimpEF jacc.org/doi/10.1016/j.…

In a subanalysis of DELIVER, #dapagliflozin reduces risk of CV death or worsening HF events in patients with #HFimpEF irrespective of degree of #LVEF improvement prior to enrollment. jacc.org/doi/10.1016/j.… #JACCHF @rudolf_deboer @texhern @mvaduganathan @mapabonp

Proud of rising star and future cardiologist @sofa_schneider, @BrighamMedRes for her first-author paper on sleep apnea and cardiac structure in HFpEF, just published in @JCardFail Doing research while in residency is no small feat, seeing it through to publication is remarkable

🚨 New in @CircAHA : Maternal CVD and pregnancy-related CV complications are rising sharply over 2 decades across >56K pregnancies across @MassGenBrigham. Pregnancy is a critical window for lifelong heart health! 🔗doi.org/10.1161/CIRCUL… @MGBResearchNews #CardioObstetrics

🔥 New in @NatureMedicine How do you communicate lifetime benefits expected with HFpEF therapies? New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx #GDMT for HFpEF has finally arrived! 🔗nature.com/articles/s4159…

@LePetitCitron_ @mchonig @MGHHeartHealth @preeclampsia @GoRedForWomen @pnatarajanmd @GarimaVSharmaMD @MinnowWalsh @malamo512 @DrMarthaGulati @BiykemB @dranulala Hi there! Our goal is at some point to make it an international registry. Stay tuned!

@mchonig @mapabonp @MGHHeartHealth @preeclampsia @GoRedForWomen @pnatarajanmd @GarimaVSharmaMD @MinnowWalsh @malamo512 @DrMarthaGulati @BiykemB @dranulala Hello. I am interested in being part of this initiative. Can you let me know if it applies to Latin America?

Peripartum🤰 HFpEF is increasingly recognized but remains poorly understood. Excited to launch the PREG-HF Registry, led by @mapabonp, aiming to characterize peripartum HF across the EF spectrum, esp. HFpEF. Please contact us if interested in joining this collaborative effort!

Excited to launch our peripartum heart failure registry! While PPCM is well recognized, HFpEF & HFmrEF in the peripartum period are under-characterized. Our goal: define this emerging population and study long-term outcomes across the EF spectrum